30, 2026 Neuropharmacology & Neurotherapeutics Apr
This medicine is considered safe for breastfeeding mothers and nursing infants
A: This product supports liver detoxification, provides antioxidant protection, and helps safeguard liver cells from oxidative damage, thanks to its carefully selected combination of ingredients
Cagrilintide is research-use only
The key regulatory milestones: FDA Breakthrough Therapy designation for MASH (September 2024) EMA PRIME designation for MASH (November 2023) China NMPA Breakthrough designation (June 2024) Phase 3 trials (SYNCHRONIZE-1 and SYNCHRONIZE-2) fully enrolled, results expected H1 of this year Estimated FDA filing: Late this year at the earliest Estimated FDA approval: Possibly next year, depending on Phase 3 results If Phase 3 results confirm Phase 2 findings, survodutide could reach the market within the next 12-24 months
NAC supports production, and liposomal glutathione offers immediate availability